Last reviewed · How we verify
NCT06954675: BREAK
Comparison of Microbiome Changes in Healthy Adults Following Ketone Ester Consumption
NA trial testing Exogenous ketone ester in Microbiome Analysis in 20 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | University of California, San Francisco |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 20 |
| Start date | 21 November 2025 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Exogenous ketone ester — full drug profile →
Conditions studied
- Microbiome Analysis — all drugs for Microbiome Analysis →
Sponsor
University of California, San Francisco
Who can join
Adults 18 to 40, any sex, with Microbiome Analysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn if a ketone ester can improve the content of the gut microbiome. The main questions it aims to answer are: * Does a ketone ester reduce age-related signatures in the gut microbiome? * What changes occur in the gut microbiome after consuming a ketone ester? Participants will: * Take a ketone ester every day for seven (7) days * Collect and ship stool samples within seven (7) days before, during, and within seven (7) days after the study period * Measure their ketone levels with a urine strip every day after having the drink * Answer questions about their typical diet on a normal day * Record their symptoms, if any arise
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06954675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exogenous ketone ester
Trials testing the same drug.
- NCT05670847 — Exogenous Ketone Esters for Drug Resistant Epilepsy · Phase 2, PHASE3 · recruiting
- NCT05674552 — Exogenous Ketone Esters for Refractory Status Epileptics · Phase 2, PHASE3 · recruiting
Other recruiting trials for Microbiome Analysis
Currently open trials in the same condition.
- NCT07165145 — Effect of Agricultural Practices on Crops, Gut Microbiome, and Human Health · NA · recruiting
- NCT06938646 — Microbiome Characterization in Fatty Pancreas · active not recruiting
Other University of California, San Francisco trials
Trials by the same sponsor.
- NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
- NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
- NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
- NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
- NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06954675 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
- Last refreshed: 26 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06954675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing